Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren Lasko, Kenneth D. Bromberg, T. Matt Hansen et al.|Nature|2017Cited by 853
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor ModelsCherrie K. Donawho, David J. Frost, Yan Luo et al.|Clinical Cancer Research|2007Cited by 770
1365 An active site PTPN2/N1 small molecule inhibitor promotes anti-tumor efficacy by sensitizing tumor cells to inflammatory signals and enhancing immune cell activityKathleen A. McGuire, Philip R. Kym, Christina K. Baumgartner et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1